Q1 EPS Forecast for Microbot Medical Increased by Analyst

Microbot Medical Inc. (NASDAQ:MBOT) – HC Wainwright increased their Q1 2026 earnings per share (EPS) estimates for Microbot Medical in a research report issued on Tuesday, April 14th. HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will post earnings of ($0.07) per share for the quarter, up from their previous forecast of ($0.09). HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Microbot Medical’s current full-year earnings is ($0.71) per share. HC Wainwright also issued estimates for Microbot Medical’s Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.08) EPS and FY2026 earnings at ($0.32) EPS.

Other equities research analysts have also recently issued research reports about the stock. B. Riley Financial initiated coverage on shares of Microbot Medical in a research note on Tuesday, February 10th. They issued a “buy” rating for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Microbot Medical in a research report on Friday, April 10th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $7.50.

Microbot Medical Price Performance

Shares of MBOT opened at $2.39 on Thursday. Microbot Medical has a 1 year low of $1.60 and a 1 year high of $4.67. The stock has a 50 day simple moving average of $2.39 and a two-hundred day simple moving average of $2.32. The firm has a market cap of $160.51 million, a P/E ratio of -8.24 and a beta of 1.19.

Microbot Medical (NASDAQ:MBOT) last announced its quarterly earnings data on Sunday, March 22nd. The biotechnology company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.02.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Goldman Sachs Group Inc. bought a new stake in Microbot Medical during the 1st quarter valued at $57,000. Geode Capital Management LLC grew its holdings in Microbot Medical by 24.7% in the 2nd quarter. Geode Capital Management LLC now owns 395,039 shares of the biotechnology company’s stock worth $996,000 after acquiring an additional 78,121 shares during the last quarter. American Century Companies Inc. bought a new stake in Microbot Medical in the 2nd quarter worth $32,000. XTX Topco Ltd purchased a new position in shares of Microbot Medical in the second quarter valued at about $43,000. Finally, Vontobel Holding Ltd. bought a new position in shares of Microbot Medical during the third quarter valued at about $94,000. Institutional investors own 16.30% of the company’s stock.

Microbot Medical Company Profile

Microbot Medical Inc (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.